Current through Register Vol. 39, No. 6, September 16, 2024
(a) The
following named diseases and conditions are declared to be dangerous to the
public health and are hereby made reportable within the time period specified
after the disease or condition is reasonably suspected to exist:
(1) acquired immune deficiency syndrome
(AIDS) - 24 hours;
(2) acute
flaccid myelitis - 7 days;
(3)
anaplasmosis - 7 days;
(4) anthrax
- immediately;
(5) arboviral
infection, neuroinvasive - 7 days;
(6) babesiosis - 7 days;
(7) botulism - immediately;
(8) brucellosis - 7 days;
(9) campylobacter infection - 24
hours;
(10) Candida auris - 24
hours;
(11) Carbapenem-Resistant
Enterobacteriaceae (CRE) - 24 hours;
(12) chancroid - 24 hours;
(13) chikungunya virus infection - 24
hours;
(14) chlamydial infection
(laboratory confirmed) - 7 days;
(15) cholera - 24 hours;
(16) Creutzfeldt-Jakob disease - 7
days;
(17) cryptosporidiosis - 24
hours;
(18) cyclosporiasis - 24
hours;
(19) dengue - 7
days;
(20) diphtheria - 24
hours;
(21) Escherichia coli, shiga
toxin-producing infection - 24 hours;
(22) ehrlichiosis - 7 days;
(23) foodborne disease, including Clostridium
perfringens, staphylococcal, Bacillus cereus, and other and unknown causes - 24
hours;
(24) gonorrhea - 24
hours;
(25) granuloma inguinale -
24 hours;
(26) Haemophilus
influenzae, invasive disease - 24 hours;
(27) Hantavirus infection - 7 days;
(28) Hemolytic-uremic syndrome - 24
hours;
(29) Hemorrhagic fever virus
infection - immediately;
(30)
hepatitis A - 24 hours;
(31)
hepatitis B - 24 hours;
(32)
hepatitis B carriage - 7 days;
(33)
hepatitis C, acute - 7 days;
(34)
human immunodeficiency virus (HIV) infection confirmed - 24 hours;
(35) influenza virus infection causing death
- 24 hours;
(36) legionellosis - 7
days;
(37) leprosy - 7
days;
(38) leptospirosis - 7
days;
(39) listeriosis - 24
hours;
(40) Lyme disease - 7
days;
(41) Lymphogranuloma venereum
- 7 days;
(42) malaria - 7
days;
(43) measles (rubeola) -
immediately;
(44) meningitis,
pneumococcal - 7 days;
(45)
meningococcal disease - 24 hours;
(46) Middle East respiratory syndrome (MERS)
- 24 hours;
(47) monkeypox - 24
hours;
(48) mumps - 7
days;
(49) nongonococcal urethritis
- 7 days;
(50) novel coronavirus
infection causing death - 24 hours;
(51) novel coronavirus infection -
immediately;
(52) novel influenza
virus infection - immediately;
(53)
plague - immediately;
(54)
paralytic poliomyelitis - 24 hours;
(55) pelvic inflammatory disease - 7
days;
(56) psittacosis - 7
days;
(57) Q fever - 7
days;
(58) rabies, human - 24
hours;
(59) rubella - 24
hours;
(60) rubella congenital
syndrome - 7 days;
(61)
salmonellosis - 24 hours;
(62)
severe acute respiratory syndrome (SARS) - 24 hours;
(63) shigellosis - 24 hours;
(64) smallpox - immediately;
(65) spotted fever rickettsiosis - 7
days;
(66) Staphylococcus aureus
with reduced susceptibility to vancomycin - 24 hours;
(67) streptococcal infection, Group A,
invasive disease - 7 days;
(68)
syphilis - 24 hours;
(69) tetanus -
7 days;
(70) toxic shock syndrome -
7 days;
(71) trichinosis - 7
days;
(72) tuberculosis - 24
hours;
(73) tularemia -
immediately;
(74) typhoid - 24
hours;
(75) typhoid carriage
(Salmonella typhi) - 7 days;
(76)
typhus, epidemic (louse-borne) - 7 days;
(77) vaccinia - 24 hours;
(78) varicella - 24 hours;
(79) vibrio infection (other than cholera) -
24 hours;
(80) whooping cough - 24
hours;
(81) yellow fever - 7 days;
and
(82) zika virus - 24
hours.
(c) In addition to the laboratory reports for
Mycobacterium tuberculosis, Neisseria gonorrhoeae, and syphilis specified in
G.S.
130A-139, laboratories shall report using
electronic laboratory reporting (ELR), secure telecommunication, or paper
reports.
(1) Isolation or other specific
identification of the following organisms or their products from human clinical
specimens:
(A) Anaplasma spp., the causes of
anaplasmosis.
(B) Any
hantavirus.
(C) Any hemorrhagic
fever virus.
(D) Arthropod-borne
virus (any type).
(E) Babesia spp.,
the cause of babesiosis.
(F)
Bacillus anthracis, the cause of anthrax.
(G) Bordetella pertussis, the cause of
whooping cough (pertussis).
(H)
Borrelia burgdorferi, the cause of Lyme disease (confirmed tests).
(I) Brucella spp., the causes of
brucellosis.
(J) Campylobacter
spp., the causes of campylobacteriosis.
(K) Candida auris.
(L) Carbapenem-Resistant Enterobacteriaceae
(CRE).
(M) Chlamydia trachomatis,
the cause of genital chlamydial infection, conjunctivitis (adult and newborn)
and pneumonia of newborns.
(N)
Clostridium botulinum, a cause of botulism.
(O) Clostridium tetani, the cause of
tetanus.
(P) Coronavirus, novel
human strain.
(Q) Corynebacterium
diphtheriae, the cause of diphtheria.
(R) Coxiella burnetii, the cause of Q
fever.
(S) Cryptosporidium spp.,
the cause of human cryptosporidiosis.
(T) Cyclospora cayetanensis, the cause of
cyclosporiasis.
(U) Dengue
virus.
(V) Ehrlichia spp., the
causes of ehrlichiosis.
(W) Shiga
toxin-producing Escherichia coli, a cause of hemorrhagic colitis, hemolytic
uremic syndrome, and thrombotic thrombocytopenic purpura.
(X) Francisella tularensis, the cause of
tularemia.
(Y) Hepatitis A
virus.
(Z) Hepatitis B virus or any
component thereof, such as hepatitis B surface antigen.
(AA) Human Immunodeficiency Virus, the cause
of AIDS.
(BB) Legionella spp., the
causes of legionellosis.
(CC)
Leptospira spp., the causes of leptospirosis.
(DD) Listeria monocytogenes, the cause of
listeriosis.
(EE) Measles
virus.
(FF) Middle East respiratory
syndrome virus.
(GG)
Monkeypox.
(HH) Mumps
virus.
(II) Mycobacterium leprae,
the cause of leprosy.
(JJ)
Plasmodium falciparum, P. malariae, P. ovale, and P. vivax, the causes of
malaria in humans.
(KK) Poliovirus
(any), the cause of poliomyelitis.
(LL) Rabies virus.
(MM) Rickettsia spp., the cause of spotted
fever rickettsiosis.
(NN) Rubella
virus.
(OO) Salmonella spp., the
causes of salmonellosis.
(PP)
Shigella spp., the causes of shigellosis.
(QQ) Smallpox virus, the cause of
smallpox.
(RR) Staphylococcus
aureus with reduced susceptibility to vancomycin.
(SS) Trichinella spiralis, the cause of
trichinosis.
(TT) Vaccinia
virus.
(UU) Varicella
virus.
(VV) Vibrio spp., the causes
of cholera and other vibrioses.
(WW) Yellow fever virus.
(XX) Yersinia pestis, the cause of
plague.
(YY) Zika virus.
(2) Isolation or other specific
identification of the following organisms from normally sterile human body
sites:
(A) Group A Streptococcus pyogenes
(group A streptococci).
(B)
Haemophilus influenzae, serotype b.
(C) Neisseria meningitidis, the cause of
meningococcal disease.
(3) Positive serologic test results, as
specified, for the following infections:
(A)
Fourfold or greater changes or equivalent changes in serum antibody titers to:
(i) Any arthropod-borne virus associated with
neuroinvasive disease.
(ii)
Anaplasma spp., the cause of anaplasmosis.
(iii) Any hantavirus or hemorrhagic fever
virus.
(iv) Chlamydia psittaci, the
cause of psittacosis.
(v)
Chikungunya virus.
(vi) Coxiella
burnetii, the cause of Q fever.
(vii) Dengue virus.
(viii) Ehrlichia spp., the causes of
ehrlichiosis.
(ix) Measles
(rubeola) virus.
(x) Mumps
virus.
(xi) Rickettsia rickettsii,
the cause of Rocky Mountain spotted fever.
(xii) Rubella virus.
(xiii) Varicella virus.
(xiv) Yellow fever virus.
(B) The presence of IgM serum
antibodies to:
(i) Any arthropod-borne virus
associated with neuroinvasive disease.
(ii) Chikungunya virus.
(iii) Chlamydia psittaci.
(iv) Dengue virus.
(v) Hepatitis A virus.
(vi) Hepatitis B virus core
antigen.
(vii) Mumps
virus.
(viii) Rubella
virus.
(ix) Rubeola (measles)
virus.
(x) Yellow fever
virus.
(4)
Laboratory results from tests to determine the absolute and relative counts for
the T-helper (CD4) subset of lymphocytes and all results from tests to
determine HIV viral load.
(5)
Identification of CRE from a clinical specimen associated with either infection
or colonization, including all susceptibility results and all phenotypic or
molecular test results.
(d) Laboratories utilizing electronic
laboratory reporting (ELR) shall report in addition to those listed under
Paragraph (c) of this Rule:
(1) All positive
laboratory results from tests used to diagnosis chronic Hepatitis C Infection,
including the following:
(A) Hepatitis C virus
antibody tests (including the test specific signal to cut-off (s/c)
ratio);
(B) Hepatitis C nucleic
acid tests;
(C) Hepatitis C
antigen(s) tests; and
(D) Hepatitis
C genotypic tests.
(2)
All HIV genotypic test results, including when available:
(A) The entire nucleotide sequence;
or
(B) The pol region sequence
(including all regions: protease (PR)/reverse transcriptase (RT) and integrase
(INI) genes, if available).
(3) All test results for Interferon Gamma
Release Assays.
Authority
G.S.
130A-134;
130A-135;
130A-139;
130A-141;
Amended
Eff. October 1, 1994; February 1, 1990;
Temporary Amendment Eff.
July 1, 1997;
Amended Eff. August 1, 1998;
Temporary
Amendment Eff. February 13, 2003; October 1, 2002; February 18, 2002; June 1,
2001;
Amended Eff. April 1, 2003;
Temporary Amendment
Eff. November 1, 2003; May 16, 2003;
Amended Eff. January 1, 2005;
April 1, 2004;
Temporary Amendment Eff. June 1, 2006;
Amended Eff. April 1, 2008; November 1, 2007; October 1, 2006;
Temporary Amendment Eff. January 1, 2010;
Temporary Amendment
Expired September 11, 2011;
Amended Eff. July 1, 2013;
Temporary Amendment Eff. December 2, 2014;
Amended Eff. October 1,
2015;
Emergency Amendment Eff. March 1, 2016;
Temporary
Amendment Eff. July 1, 2016;
Amended Eff. January 1, 2018; October
1, 2016;
Pursuant to
G.S.
150B-21.3A, rule is necessary without
substantive public interest Eff. January 9, 2018;
Amended Eff.
October 1, 2018;
Emergency Amendment Eff. February 17,
2020;
Temporary Amendment Eff. April 24, 2020;
Amended
Eff. April 1, 2021; July 1, 2020.
